Table 5.
Negative budding (n = 131) HR (95% CI) | Positive budding (n = 81) HR (95% CI) | P value | High TSR (n = 172) HR (95% CI) | Low TSR (n = 40) HR (95% CI) | P value | |
---|---|---|---|---|---|---|
3-year overall mortality | ||||||
Crudea | 1 (reference) | 0.70 (0.51–0.97) | 0.031 | 1 (reference) | 1.06 (0.72–1.57) | 0.756 |
Adjustedb | 1 (reference) | 0.81 (0.58–1.15) | 0.241 | 1 (reference) | 1.01 (0.66–1.55) | 0.965 |
3-year disease-specific mortality | ||||||
Crudea | 1 (reference) | 0.64 (0.44–0.93) | 0.020 | 1 (reference) | 0.97 (0.61–1.52) | 0.884 |
Adjustedb | 1 (reference) | 0.74 (0.50–1.11) | 0.143 | 1 (reference) | 0.89 (0.54–1.47) | 0.643 |
Follow-up ended on December 31, 2017. In patients operated in 2018, follow-up ended 30 days after surgery.
aCrude was adjusted with treatment (local ablation/TACE/palliative).
bAdjustment for age (continuous), sex (female/male), Charlson Comorbidity Index (0–1, 2 or more), stage (1, 2 or more), cirrhosis (no/yes), year of surgery/diagnosis (1983–2005 and 2006–2018), Child–Pugh index (A, B or C) and tumour grade (1–2 and 3) (local ablation/TACE/palliative).